Delivery Order SPE2DB22D1002-SPE2DB25FLHQ8
Award Date 9/15/25
Potential Completion Date 10/6/25
Potential Value $1.8K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of HYPERRAB 300 Unit/ML Vial 5ML, a rabies immunoglobulin product used for post-exposure prophylaxis. This non-set-aside, firm fixed-price delivery order carries a ceiling value of $21,489.60 and is scheduled for completion by September 29, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a $10,744.80 delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of HYPERRAB 300 Unit/mL Vial 5mL, a rabies immunoglobulin product used for post-exposure prophylaxis. This firm fixed-price, competitively awarded delivery order is scheduled for completion by August 20, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract includes no set-aside designation,...
- The Defense Department's Medical Supply Chain awarded a delivery order valued at $7,163.24 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML, a rabies immune globulin product used in post-exposure prophylaxis treatment. Issued on September 7, 2025, with completion due by September 8, 2025, this firm fixed-price delivery order represents a competitively awarded contract with no set-aside designation. The product will be delivered to AmerisourceBergen's corporate office location in...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of HYPERRAB 300 Unit/mL vials at a ceiling value of $1,039.53, with final completion required by August 18, 2025. This is a firm fixed-price delivery order issued without set-aside designation, indicating open competition. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, executed this order...
- The Defense Logistics Agency awarded a $21,489.60 delivery order to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/mL vial 5mL, a rabies immunoglobulin product used for post-exposure prophylaxis. The contract, issued on August 25, 2025, with an ultimate completion date of September 16, 2025, represents a firm fixed price delivery order with no set-aside designation. Performance will occur at the contractor's facility in Conshohocken, Pennsylvania. This award is issued as a child order under...
- The Defense Logistics Agency awarded a delivery order valued at $17,908 to AmerisourceBergen Drug Corp for the supply of HYPERRAB 300 Unit/mL vial 5mL, a rabies immunoglobulin product. This firm fixed-price, non-set-aside delivery order was awarded on August 20, 2025, with an ultimate completion date of September 11, 2025. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $3,581.62 delivery order to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML Vial 5ML, a rabies immunoglobulin pharmaceutical product. This firm fixed price delivery order was competitively awarded without set-aside designation and is scheduled for ultimate completion on September 8, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency has awarded a delivery order valued at $3,581.62 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML Vial 5ML, a rabies immunoglobulin product used for post-exposure prophylaxis. The non-competitive delivery order is scheduled for completion by June 23, 2025, and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. This award utilizes firm fixed pricing under a delivery order contract type, reflecting the standardized...
- The Defense Logistics Agency awarded a delivery order valued at $8,895.79 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML Vial 5ML, a rabies immunoglobulin product used for post-exposure prophylaxis. This non-competed, firm fixed-price delivery order has a completion date of August 8, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $5,372.40 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML Vial 5ML, a rabies immunoglobulin product used for post-exposure prophylaxis. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 15, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting the contractor's...